- Home
- CATX vs SLGL Comparison
CATX vs SLGL Comparison
Compare CATX & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CATX | SLGL |
|---|---|---|
| Founded | 1983 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.5M | 218.9M |
| IPO Year | 2018 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CATX | SLGL |
|---|---|---|
| Price | $1.23 | $66.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 4 |
| Target Price | $11.43 | ★ $152.50 |
| AVG Volume (30 Days) | ★ 2.5M | 30.3K |
| Earning Date | 11-09-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.06 | $28.81 |
| 52 Week High | $6.16 | $97.97 |
Technical Indicators
Market Signals| Indicator | CATX | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 21.38 | 48.18 |
| Support Level | N/A | $61.35 |
| Resistance Level | $3.67 | $81.22 |
| Average True Range (ATR) | 0.23 | 3.88 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 7.37 | 51.82 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.